Clinical Trials for COVID‐19: Can we Better Use the Short Window of Opportunity?
Open Access
- 14 May 2020
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (4), 730-733
- https://doi.org/10.1002/cpt.1891
Abstract
The scientific community has risen to the Covid‐19 challenge, coming up with an impressive list of candidate drugs and vaccines targeting an array of pharmacological and immunological mechanisms. Yet, generating clinical evidence of efficacy and safety of these candidate treatments may be frustrated by the absence of comprehensive trial coordination mechanisms. Many small stand‐alone trials and observational studies of single‐agent interventions are currently running or in planning; many of these will likely not deliver robust results that could support regulatory and patient‐level treatment decisions. We here discuss actions that all stakeholders in the clinical trial ecosystem need to take to ensure that the window of opportunity during this pandemic will not shut, both for patients in need of treatment and for researchers to conduct decision‐relevant clinical trials.This publication has 6 references indexed in Scilit:
- Compassionate Use of Remdesivir for Patients with Severe Covid-19The New England Journal of Medicine, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Plea for multitargeted interventions for severe COVID-19The Lancet Infectious Diseases, 2020
- Flooded by the torrent: the COVID-19 drug pipelineThe Lancet, 2020
- Global coalition to accelerate COVID-19 clinical research in resource-limited settingsThe Lancet, 2020
- Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A reviewContemporary Clinical Trials Communications, 2018